Mallinckrodt plc ("Mallinckrodt") and Endo, Inc. (OTCQX: NDOI) ("Endo") today reported significant progress toward their proposed merger to create a global, scaled, diversified therapeutics leader.

Malvern-based Endo has approved $3.5 million in retention bonuses for its key executives as it works toward a merger with ...

Mallinckrodt and Endo, pharmaceutical companies that have each encountered business struggles, announced Thursday a $6.7 billion merger that they contend will result in a combined entity with the ...

Two companies forced to file for bankruptcy protection due to opioid litigation in the US – Mallinckrodt and Endo – have agreed to join forces via a $6.7 billion merger. According to the ...

Endo Inc (NDOI) reports a mixed quarter with revenue challenges in key segments but remains optimistic about future growth through strategic product launches and mergers.

Mallinckrodt, Endo Merger To Create Pharma Entity Valued At $7 Billion Mallinckrodt and Endo are merging in a $6.7 billion deal, with a pro forma NYSE listing and $900 million in financing.

Endo Inc.'s first quarter 2025 financial results ... We had a number of moving pieces during the quarter, including our announced merger with Mallinckrodt and the divestiture of International ...

S-4 Registration Statement Effective; HSR Waiting Period ExpiredIrish High Court Approves Convening of Shareholder Meetings Shareholder Vote Scheduled for June 13 DUBLIN and MALVERN, Pa.